NEW DATA ON THE SAFETY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: THE CONCEPT OF THE HIGH CLASS-SPECIFIC CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS IS OUTDATED
The results of the PRECISION trial were published in late 2016. During this trial, a total of 24,081 patients at high cardiovascular risk took celecoxib 200-400 mg/day, naproxen 750–1000 mg/day or ibuprofen 1800–2400 mg/day for more than 1.5 years (20.3±16.0 months). The findings show that the frequ...
Saved in:
Main Authors: | A. E. Karateev, D. S. Novikova, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2017-04-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2366 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN PATIENTS WITH HIGH CARDIOVASCULAR RISK
by: Yu. A. Olyunin
Published: (2017-07-01) -
Results of the PRECISION study: Could an answer be given to the question of how safe coxibs versus traditional NSAIDs are in treating patients at high risk for cardiovascular events?
by: E. V. Dovgan
Published: (2017-09-01) -
WHY IS THE STUDY OF THE COMPLEX SAFETY OF CELECOXIB FOR ARTHRITIS, WHICH IS CALLED PRECISION, LAST BUT NOT LEAST?
by: Yu. V. Muravyev
Published: (2017-07-01) -
How effective is the average therapeutic dose of a nonsteroidal anti-inflammatory drug in osteoarthritis?
by: A. E. Karateev
Published: (2019-03-01) -
Over-the-counter naproxen in rheumatology practice: scope and therapeutic benefits
by: E. S. Filatova, et al.
Published: (2020-11-01)